Business Segments Evotec SE CBOE

Stocks

Market Closed - CBOE 09:00:00 11/09/2026 pm IST			5-day change	1st Jan Change
3.217 ^EUR	0.00%		0.00%	-40.37%

09/09	Evotec Initiates Phase 1 Trial of Potential Smallpox, Mpox Treatment	MT
09/09	Evotec Commences Early-stage Study of Potential Orthopoxvirus Therapy	MT

Breakdown by Business Segment (EUR)

Fiscal Period: December	2021	2022	2023	2024	2025
Life Sciences Tools and Services
Discovery and Preclinical Development	-	-	-	61Cr	53Cr
Gross Profit	-	-	-	10Cr	4.68Cr
EBITDA	-	-	-	1.27Cr	-1.2Cr
D&A	-	-	-	7.72Cr	7.48Cr
Operating Income	-	-	-	-13Cr	-7.45Cr
	-	-	-	-	26Cr
Just - Evotec Biologics	-	-	-	19Cr	26Cr
Gross Profit	-	-	-	1.36Cr	6.74Cr
EBITDA	-	-	-	98.69L	5.32Cr
D&A	-	-	-	2.44Cr	2.47Cr
Operating Income	-	-	-	-1.64Cr	1.83Cr
EVT Innovate	15Cr	20Cr	27Cr	-	-
Gross Profit	-	-	-	-	-
EBITDA	-1.75Cr	-66.02L	10L	-	-
D&A	39.91L	50.87L	54.47L	-	-
Operating Income	-2.21Cr	-1.17Cr	-44.89L	-	-
	-	-	-	-	53Cr
EVT Execute	61Cr	74Cr	74Cr	-	-
Gross Profit	-	-	-	-	-
EBITDA	12Cr	11Cr	6.54Cr	-	-
D&A	6.36Cr	7.66Cr	8.75Cr	-	-
Operating Income	6.31Cr	3.25Cr	-4.3Cr	-	-
Transition	-	-	-	-	-
Intersegment Elimination	-14Cr	-19Cr	-22Cr	-12.08L	-5L
Gross Profit	-	-	-	-9L	-17T
Operating Income	-	-	-	-	-

Geographical breakdown of sales (EUR)

Fiscal Period: December	2021	2022	2023	2024	2025
USA	-	-	46Cr	45Cr	43Cr
Total Assets	-	-	22Cr	26Cr	22Cr
Switzerland	-	-	6.49Cr	11Cr	16Cr
Total Assets	-	-	-	-	-
Total Assets	-	-	26.34L	-	-
Total Assets	-	-	-	-	-
Total Assets	-	-	-	-	-
	-	-	-	-	1.13Cr
Rest of the World	-	-	9.52Cr	8.23Cr	7.71Cr
	-	-	-	-	6.17Cr
United Kingdom	-	-	8.64Cr	9.25Cr	6.17Cr
Total Assets	-	-	22Cr	21Cr	18Cr
	-	-	-	-	43Cr
Germany	-	-	3.41Cr	3.29Cr	2.53Cr
Total Assets	-	-	15Cr	15Cr	19Cr
	-	-	-	-	7.71Cr
France	-	-	3.2Cr	1.99Cr	1.99Cr
Total Assets	-	-	34Cr	33Cr	8.97Cr
Total Assets	-	-	26Cr	24Cr	23Cr
	-	-	-	-	16Cr
Unallocated	-	-	-	1.44Cr	1.13Cr
Europe	-	-	-	-	-
	-	-	-	-	1.99Cr
	-	-	-	-	2.53Cr